Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $3.64B | $3.91B | $4.28B | $4.61B | $3.57B | $4.01B | $4.35B | $4.80B | $5.37B | $5.94B |
| Revenue growth | — | 7.4% | 9.3% | 7.7% | -22.6% | 12.6% | 8.3% | 10.4% | 11.9% | 10.5% |
| Operating income | $588M | $578M | $555M | $612M | $564M | $560M | $540M | — | — | — |
| Operating margin | 16.1% | 14.8% | 13.0% | 13.3% | 15.8% | 13.9% | 12.4% | — | — | — |
| Net income | $248M | $271M | $292M | $359M | $284M | $412M | $271M | $352M | $456M | $566M |
| Net margin | 6.8% | 6.9% | 6.8% | 7.8% | 8.0% | 10.3% | 6.2% | 7.3% | 8.5% | 9.5% |
| EPS (diluted) | $2.59 | $2.84 | $2.93 | $3.61 | $2.85 | $4.11 | $2.70 | $3.47 | $4.46 | $5.54 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $640M | $658M | $762M | $635M | $705M | $716M | $706M | $851M | $1.00B | $1.18B |
| Capital expenditures | $178M | $226M | $255M | $372M | $393M | $546M | $584M | $583M | $643M | $736M |
| Free cash flow | $463M | $433M | $508M | $263M | $312M | $170M | $122M | $268M | $360M | $439M |
| Share buybacks | $65.6M | $38.1M | $0.00 | $45.9M | $6.10M | $0.00 | $0.00 | $0.00 | $31.1M | $158M |
| Dividends paid | $83.8M | $91.5M | $101M | $109M | $112M | $112M | $99.0M | $60.4M | $62.8M | $71.1M |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $40.5M | $54.4M | $69.2M | $60.0M | $186M | $49.4M | $21.8M | $69.1M | $85.4M | $72.2M |
| Total assets | $4.68B | $4.86B | $5.17B | $6.08B | $6.45B | $6.86B | $5.64B | $6.10B | $6.53B | $7.09B |
| Total liabilities | $3.61B | $3.25B | $3.36B | $4.15B | $4.44B | $4.47B | $3.77B | $3.81B | $3.69B | $3.81B |
| Shareholders' equity | $736M | $1.15B | $1.28B | $1.35B | $1.59B | $1.91B | $1.31B | $1.65B | $2.07B | $2.44B |
| Retained earnings | -$1.45B | -$1.18B | -$885M | -$527M | -$242M | $142M | $116M | $407M | $797M | $1.29B |
| Shares (wtd avg diluted) | 99.5M | 99.3M | 99.8M | 99.4M | 99.8M | 100M | 100M | 101M | 102M | 102M |
Every figure is extracted from Encompass Health Corp’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.